Printer Friendly

CNS, INC. GETS APPROVAL TO MARKET NASAL DILATOR

 MINNEAPOLIS, Oct. 12 /PRNewswire/ -- CNS, Inc., (NASDAQ: CNXS) today announced it has received approval from the U.S. Food and Drug Administration to begin marketing the Breathe Right(TM) external nasal dilator, which enhances nasal breathing without the use of drugs.
 Breathe Right, which is approximately the size and appearance of a small adhesive bandage, is a single-use disposable product which is placed across the nose and exerts a gentle lifting force to instantly open the nasal passages. Breathe Right is an alternative to oral and nasal spray decongestants and is ideal for nighttime use.
 Breathe Right will be marketed to hospitals and home care providers for use on patients with respiratory ailments such as chronic lung disease, particularly those patients receiving oxygen therapy. The product will also be marketed as an over-the-counter (non-prescription) health care product for relief of nasal congestion from such causes as allergies, sinusitis and the common cold.
 "We are excited to begin marketing Breathe Right," said Daniel E. Cohen, M.D., chairman and chief executive officer. "During our clinical trials, we witnessed an enthusiastic response from patients, particularly for the treatment of night-time nasal congestion. Many patients reported improved sleep and reduced snoring as a result of using the product.
 "The introduction of Breathe Right positions the company to participate for the first time in the over-the-counter health market. We anticipate that the product will be a significant contributor to our business mix as we gain exposure to markets that include the approximately 35 million Americans who suffer from allergies and sinusitis and 90 million households affected by colds."
 The company is prepared to begin shipments of the product immediately.
 CNS, Inc., based in Minneapolis, designs, manufactures and markets medical devices used principally in the diagnosis and treatment of sleep disorders.
 -0- 10/12/93
 /CONTACT: Daniel E. Cohen or Richard E. Jahnke of CNS, 612-474-7600; or Curt Swenson of Swenson/Falker Associates, 612-371-0000, for CNS/
 (CNXS)


CO: CNS, Inc. ST: Minnesota IN: HEA SU: PDT

CP-DB -- MN013 -- 1302 10/12/93 16:51 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 12, 1993
Words:340
Previous Article:DAMARK INTERNATIONAL, INC. REPORTS THIRD-QUARTER AND FIRST THREE QUARTERS' RESULTS
Next Article:NOSTALGIA NETWORK ANNOUNCES FORMATION OF SPECIAL COMMITTEE TO REVIEW FINANCING PROPOSALS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters